Chris M. Storgard, M.D., is the Chief Medical Officer (CMO) at Design Therapeutics. Dr. Storgard previously served as CMO at ADARx Pharmaceuticals, where he transitioned the organization from research to development-stage operations, overseeing the advancement of multiple clinical programs, including preparations for the company’s first global Phase 3 program. Prior to that, he held CMO positions at Heron Therapeutics, where he oversaw teams that secured multiple U.S. and European approvals, and Fate Therapeutics. Previously, Dr. Storgard served as Vice President of Clinical Research and Development at Ardea Biosciences (an AstraZeneca Company), where he led the global clinical program for lesinurad, culminating in regulatory approvals in multiple major markets. His career also includes clinical development roles at Biogen Idec and Amgen, as well as clinical and academic appointments at the Mayo Clinic, Scripps Mercy Hospital and The Scripps Research Institute. Dr. Storgard received his M.D. and BSc degrees from the University of Saskatchewan and is board-certified in Rheumatology and Internal Medicine.